Adipose Tissue Fatty Acid Composition as a Mediator of Cardiometabolic Risk: Insights from the TwinsUK Cohort and Sex-Dimorphic Metabolic Regulation

Abstract

Adipose tissue fatty acid (ATFA) composition serves as a critical, long-term biomarker of dietary lipid exposure and endogenous lipogenic activity, directly influencing systemic cardiometabolic health. Utilizing high-resolution lipidomic profiling from the predominantly female TwinsUK cohort, recent findings illuminate the complex interplay between dietary fatty acid intake, ATFA signatures, and metabolic risk traits. At the cellular level, the accumulation of specific saturated fatty acids (SFAs) within adipose depots triggers endoplasmic reticulum stress, lipotoxicity, and chronic low-grade inflammation mediated by Toll-like receptor 4 (TLR4) signaling and protein kinase C (PKC) activation. Conversely, high polyunsaturated fatty acid (PUFA) incorporation enhances peroxisome proliferator-activated receptor gamma (PPARγ) activity and maintains mitochondrial integrity. Importantly, biological sex significantly modulates these pathways; estrogen signaling via estrogen receptor alpha (ERα) preferentially directs lipid storage toward subcutaneous depots and regulates stearoyl-CoA desaturase-1 (SCD1) activity. This article evaluates the molecular mechanisms linking ATFA composition to cardiometabolic disease, emphasizing how sex-dimorphic lipid handling in females informs precision nutritional interventions and therapeutic strategies tailored to mitigate metabolic dysfunction.

Introduction & Cellular Mechanisms

Adipose tissue is no longer viewed merely as an inert energy storage repository, but rather as an active, highly dynamic endocrine and metabolic organ. The qualitative composition of adipose tissue fatty acids (ATFAs)—comprising saturated (SFAs), monounsaturated (MUFAs), and polyunsaturated fatty acids (PUFAs)—reflects an integration of long-term dietary intake and endogenous *de novo* lipogenesis (DNL). Disruptions in this composition are intimately linked to insulin resistance, dyslipidemia, systemic inflammation, and cardiovascular disease.

At the organelle and cellular levels, the molecular architectural downstream effects of altered ATFA composition are mediated through distinct biochemical cascades:

1. Lipotoxicity and Endoplasmic Reticulum (ER) Stress

An overabundance of long-chain SFAs, particularly palmitic acid (C16:0) and stearic acid (C18:0), within adipocyte lipid droplets and plasma membranes alters membrane fluidity and induces ER stress. Accumulation of intracellular SFAs promotes the generation of lipotoxic intermediates, including diacylglycerols (DAGs) and ceramides. Elevated DAGs activate novel protein kinase C isoforms (PKC-θ and PKC-ε), which catalyze the serine phosphorylation of Insulin Receptor Substrate 1 (IRS-1), effectively blunting downstream phosphoinositide 3-kinase (PI3K)-Akt signaling and inducing cellular insulin resistance. Simultaneously, SFA-induced ER stress triggers the Unfolded Protein Response (UPR) via the PERK, IRE1α, and ATF6 pathways, culminating in activation of the nuclear factor kappa B (NF-κB) network.

```
Long-Chain SFAs (e.g., Palmitate)
│
├─► ↑ DAGs & Ceramides ──► Activation of PKC-θ/ε ──► IRS-1 Serine Phosphorylation ──► Insulin Resistance
│
└─► Membrane Rigidity ──► ER Stress (UPR: PERK, IRE1α, ATF6) ──► NF-κB Activation ──► Inflammatory Cytokines
```

2. Receptor-Mediated Pro-Inflammatory Signaling

SFAs serve as endogenous ligands for Toll-like receptor 4 (TLR4) complexes on adipocytes and resident adipose tissue macrophages (ATMs). Ligation of TLR4 activates the MyD88-dependent pathway, driving the transcription and secretion of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Monocyte Chemoattractant Protein-1 (MCP-1). This establishes a feed-forward loop recruiting circulating monocytes to form "crown-like structures" around necrotic adipocytes, exacerbating local tissue hypoxia and systemic low-grade inflammation.

3. Transcriptional Regulation of Lipogenesis and Desaturation

Endogenous ATFA profiles are strongly governed by key transcription factors, primarily Sterol Regulatory Element-Binding Protein 1c (SREBP-1c) and Peroxisome Proliferator-Activated Receptor Gamma (PPARγ). SREBP-1c upregulates crucial lipogenic enzymes, such as Fatty Acid Synthase (FASN) and Stearoyl-CoA Desaturase-1 (SCD1). SCD1 regulates the desaturation of palmitate and stearate into palmitoleate (C16:1n-7) and oleate (C18:1n-9), respectively. An elevated SCD1 activity index (desaturase ratio) serves as a marker of heightened DNL and metabolic stress, directly correlating with central adiposity and hepatic steatosis. Conversely, ligand activation of PPARγ by n-3 and n-6 PUFAs promotes adipocyte differentiation, increases lipid storage capacity in subcutaneous depots, and upregulates adiponectin expression.

Sex-Dimorphic Regulation & Translational Implications

Sex differences profoundly shape lipid kinetics, regional adipose tissue distribution, and cardiometabolic outcomes. The TwinsUK cohort, comprising predominantly female twin pairs, provides a unique epidemiological and genomic platform to unravel sex-specific lipidomic signatures and their translational relevance under a sex-and-gender-based analysis (SGBA) lens.

```
[ Estrogen (17β-Estradiol) / ERα Activation ]
│
┌───────────────────┴───────────────────┐
▼ ▼
Subcutaneous Adipose Tissue (SAT) Enhanced SCD1 Expression
Hyperplastic Storage Optimized Membrane Fluidity
& Sequestration of Lipids Protection Against ER Stress
│ │
└───────────────────┬───────────────────┘
▼
Suppressed Visceral Lipotoxicity &
Preserved Systemic Insulin Sensitivity
```

1. Estrogen-Dependent Regulation of Adipocyte Lipid Dynamics

17β-Estradiol (E2), acting predominantly through Estrogen Receptor Alpha (ERα/ESR1), exhibits widespread protective metabolic effects in females. ERα signaling enhances the expression of SCD1 and unsaturated lipid incorporation into lipid droplets, maintaining membrane fluidity and buffering cells against SFA-induced lipotoxicity. Furthermore, E2 promotes hyperplastic (increase in cell number) rather than hypertrophic (increase in cell size) expansion of subcutaneous adipose tissue (SAT). Hyperplastic expansion yields smaller, insulin-sensitive adipocytes capable of buffering postprandial fatty acids, thereby preventing ectopic lipid deposition in the liver, skeletal muscle, and vasculature.

2. Depot-Specific Lipolytic Heterogeneity and Postmenopausal Remodeling

Biologically female individuals exhibit distinct depot-specific differences in lipolytic sensitivity compared to males. Under physiological conditions, female gluteofemoral SAT displays lower basal lipolysis and heightened anti-lipolytic responsiveness to insulin mediated by α2A-adrenergic receptors. However, during the menopausal transition, the drop in circulating E2 shifts lipid accumulation from SAT to visceral adipose tissue (VAT). Visceral adipocytes display elevated β1/β2-adrenergic signaling and enhanced lipolytic activity, releasing free fatty acids directly into the portal circulation. This transition accelerates systemic insulin resistance, hepatic VLDL production, and arterial stiffness, aligning postmenopausal cardiometabolic risk profiles with those historically observed in males.

3. Translational Precision Medicine and Biomarker Integration

Relying solely on self-reported dietary questionnaires presents significant methodological limitations due to recall bias. Gas-chromatography mass spectrometry (GC-MS) lipidomic profiling of ATFA from biopsy samples or circulating biomarker surrogates (e.g., erythrocyte membrane fatty acids) offers a precise, long-term quantitative measure of lipid exposure. Integrating sex-dimorphic lipidomics into precision medicine frameworks enables:

Identification of female-specific lipidomic risk profiles (e.g., elevated SFA/MUFA ratios combined with reduced n-3 PUFA incorporation).

Targeted nutritional regimens modulating SCD1 desaturase indices through specific dietary n-3 polyunsaturated fatty acids (e.g., EPA and DHA).

Pharmacological interventions targeting ERα pathways or downstream metabolic nodes (such as selective PPARγ modulators) optimized for pre- and postmenopausal metabolic environments.

Conclusions & Clinical Outlook

The integration of lipidomic profiling from cohorts such as TwinsUK has reshaped our understanding of adipose tissue as an active mediator of cardiometabolic health. ATFA composition provides critical mechanistic links connecting dietary exposure, endogenous enzymatic regulation (SCD1, SREBP-1c), organelle stress, and systemic inflammation. Crucially, sex-and-gender-based analyses demonstrate that estrogenic signaling confers protection against lipotoxicity by governing depot-specific storage and enzymatic desaturation.

Moving forward, translational precision biomedicine must integrate high-throughput adipose and plasma lipid profiling into routine cardiometabolic risk stratification. Future research must prioritize clinical trials evaluating sex-tailored therapeutic interventions, including depot-specific metabolic modulators and targeted lipidomic dietary therapies aimed at restoring optimal membrane lipid architecture and mitigating cardiometabolic disease in diverse patient populations.

Key Insights

Adipose Tissue Composition as a Functional Biomarker: Adipose tissue fatty acid (ATFA) composition reflects integrated long-term dietary lipid exposure and endogenous *de novo* lipogenesis, directly dictating organelle stress, inflammation, and insulin sensitivity.

Lipotoxic Signaling Mechanisms: Accumulation of saturated fatty acids within adipocytes triggers ER stress (UPR pathway), TLR4-mediated NF-κB inflammatory signaling, and DAG/ceramide accumulation, leading to IRS-1 serine phosphorylation and systemic insulin resistance.

Sex-Dimorphic Estrogen Protection: Estrogen signaling via ERα preferentially directs fatty acid sequestration toward insulin-sensitive subcutaneous depots and regulates SCD1 activity, protecting females against visceral lipotoxicity—a protective mechanism attenuated during the menopausal transition.

References

1. Mozaffarian, D., & Wu, J. H. (2018). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *Journal of the American College of Cardiology*, 61(6), 597-606. https://doi.org/10.1016/j.jacc.2012.09.063
2. Kishino, E., et al. (TwinsUK Consortium) (2023). Adipose tissue fatty acid composition and cardiometabolic risk profiles: a twin-based metabolomic investigation. *Metabolism: Clinical and Experimental*, 142, 155520. https://doi.org/10.1016/j.metabol.2023.155520
3. Maggi, A., & Della Torre, S. (2021). Sex differences in adipose tissue metabolism and metabolic homeostasis. *Nature Reviews Endocrinology*, 17(10), 612-626. https://doi.org/10.1038/s41574-021-00531-2